Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open, Dose Increasing Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Primary Efficacy of xy0206 Tablets in Relapsed / Refractory Acute Myeloid Leukemia Subjects

NCT04471064 is registered in ClinicalTrials.gov with Shijiazhuang Yiling Pharmaceutical Co. Ltd as lead sponsor.

NCT NCT04471064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04471064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open, Dose Increasing Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Primary Efficacy of xy0206 Tablets in Relapsed / Refractory Acute Myeloid Leukemia Subjects
Lead sponsor
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
September 15, 2020
Completion date
February 29, 2024
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia